TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients 英文论文文献.docVIP

Mahner et al. BMC Cancer 2010, 10:139 /1471-2407/10/139 RESEARCH ARTICLE Open Access TIMP-1 and VEGF-165 serum concentration during Research article first-line therapy of ovarian cancer patients Sven Mahner*?1, Linn Woelber?1, Christine Eulenburg2, Joerg Schwarz1,4, Walter Carney3, Fritz Jaenicke1, Karin Milde- Langosch1 and Volkmar Mueller1 Abstract Background: Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TI